{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T11:16:45Z","timestamp":1761218205370,"version":"3.37.3"},"reference-count":20,"publisher":"BMJ","issue":"9","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2019,8,14]]},"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To survey current prescribing practices of psychotropic drugs by child and adolescent eating disorder (CAED) psychiatrists in the treatment of anorexia nervosa (AN).<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Cross-sectional self-administered survey.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>All children and young people eating disorder services (CYP EDS) in England during a national training programme.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>44 CAED psychiatrists practising in CYP EDS in England.<\/jats:p><\/jats:sec><jats:sec><jats:title>Primary and secondary outcome measures<\/jats:title><jats:p>CAED psychiatrists completed a questionnaire regarding the pattern of psychopharmacological care in AN that they provide and the medication treatment pattern at their CYP EDS. Secondary outcome measures included the process of continuing pharmacotherapy from secondary care to primary care.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 77 CYP EDS representing every team in England, 44 teams represented by a CAED psychiatrist responded, despite 13 having no psychiatrists in post at the time of the study (response rate 69%). Most (40%) respondents estimated that &lt;10% of patients with AN were prescribed psychotropic medications. Olanzapine was reported as the most commonly prescribed medication for AN by 38% of the respondents, followed by fluoxetine (29%) and sertraline (10%). The most common minimum olanzapine initiation dose in this study was at 2.5\u2009mg\/day for a duration of 2\u20134 weeks, reaching a maximum dose of 5\u2009mg\/day. Most (68%) reviewed medications every week (30%) or every 2\u2009weeks (38%). Over 50% of the respondents reported continuation of olanzapine prescribing within the CYP EDS teams.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This nationally representative survey showed that despite a lack of evidence, psychotropic medications are commonly prescribed to a minority of patients, most frequently, olanzapine. Further evidence is needed on which patients may potentially benefit from pharmacotherapy as an adjunct to psychological interventions.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2019-031707","type":"journal-article","created":{"date-parts":[[2019,9,21]],"date-time":"2019-09-21T11:05:38Z","timestamp":1569063938000},"page":"e031707","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Survey on self-reported psychotropic drug prescribing practices of eating disorder psychiatrists for the treatment of young people with anorexia nervosa"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7202-0017","authenticated-orcid":false,"given":"Maedeh","family":"Y Beykloo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dasha","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mima","family":"Simic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8934-347X","authenticated-orcid":false,"given":"Ruth","family":"Brauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Mills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian C K","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,9,20]]},"reference":[{"key":"2024052015073319000_9.9.e031707.1","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.cbpra.2015.09.002","article-title":"Incorporating social support in the treatment of anorexia nervosa: special considerations for older adolescents and young adults","volume":"23","author":"Pisetsky","year":"2016","journal-title":"Cogn Behav Pract"},{"key":"2024052015073319000_9.9.e031707.2","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/erv.2240","article-title":"Psychotropic drug treatment in anorexia nervosa. search for differences in Efficacy\/Tolerability between adolescent and Mixed-age population","volume":"21","author":"Balestrieri","year":"2013","journal-title":"European Eating Disorders Review"},{"key":"2024052015073319000_9.9.e031707.3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.prostaglandins.2017.02.002","article-title":"Integrating multi-omics biomarkers and postprandial metabolism to develop personalized treatment for anorexia nervosa","volume":"132","author":"Shih","year":"2017","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"2024052015073319000_9.9.e031707.4","unstructured":"NICE NIfHaCE . Eating disorders: recognition and treatment, 2018. Available: https:\/\/www.nice.org.uk\/guidance\/ng69 [Accessed 12 Oct 2018]."},{"key":"2024052015073319000_9.9.e031707.5","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1177\/1087054714536047","article-title":"Adhd drug prescribing trend is increasing among children and adolescents in Hong Kong","volume":"21","author":"KKC","year":"2017","journal-title":"Journal of attention disorders"},{"key":"2024052015073319000_9.9.e031707.6","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2004.064956"},{"key":"2024052015073319000_9.9.e031707.7","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-2008"},{"key":"2024052015073319000_9.9.e031707.8","first-page":"173","article-title":"A review of medication use for children and adolescents with eating disorders","volume":"16","author":"Couturier","year":"2007","journal-title":"J Can Acad Child Adolesc Psychiatry"},{"key":"2024052015073319000_9.9.e031707.9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/erv.988","article-title":"Atypical antipsychotics and anorexia nervosa: a review","volume":"18","author":"McKnight","year":"2010","journal-title":"European Eating Disorders Review"},{"key":"2024052015073319000_9.9.e031707.10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1475-3588.2009.00535.x","article-title":"Drug prescribing in child and adolescent eating disorder services","volume":"15","author":"Gowers","year":"2010","journal-title":"Child Adolesc Ment Health"},{"key":"2024052015073319000_9.9.e031707.11","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jadohealth.2015.03.021","article-title":"Use of Psychopharmacologic medications in adolescents with restrictive eating disorders: analysis of data from the National eating disorder quality improvement collaborative","volume":"57","author":"Monge","year":"2015","journal-title":"Journal of Adolescent Health"},{"key":"2024052015073319000_9.9.e031707.12","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s40519-018-0520-3","article-title":"Psychotropic usage by patients presenting to an academic eating disorders program","volume":"23","author":"Mizusaki","year":"2018","journal-title":"Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity"},{"key":"2024052015073319000_9.9.e031707.13","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/eat.22037","article-title":"Psychotropic medication use in anorexia nervosa between 1997 and 2009","volume":"45","author":"Fazeli","year":"2012","journal-title":"International Journal of Eating Disorders"},{"key":"2024052015073319000_9.9.e031707.14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1665.2004.02154.x"},{"key":"2024052015073319000_9.9.e031707.15","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e328080ca31"},{"key":"2024052015073319000_9.9.e031707.16","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2008.07121900"},{"key":"2024052015073319000_9.9.e031707.17","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2010.0131"},{"key":"2024052015073319000_9.9.e031707.18","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2010.0139"},{"key":"2024052015073319000_9.9.e031707.19","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/erv.843","article-title":"Atypical antipsychotics in severe anorexia nervosa in children and adolescents\u2014review and case reports","volume":"16","author":"Mehler-Wex","year":"2008","journal-title":"European Eating Disorders Review"},{"key":"2024052015073319000_9.9.e031707.20","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1176\/appi.ajp.2018.18101125","article-title":"Olanzapine versus placebo in adult outpatients with anorexia nervosa: a randomized clinical trial","volume":"176","author":"Attia","year":"2019","journal-title":"American Journal of Psychiatry"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2019-031707","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T22:16:29Z","timestamp":1716243389000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2019-031707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":20,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,9,20]]},"published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1136\/bmjopen-2019-031707"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2019-031707","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2019,9]]}}}